Last update 31 Mar 2025

Ustekinumab-stba

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Ustekinumab Biosimilar (Celltrion, Inc.), 乌司奴单抗生物类似药(Celltrion, Inc.), CT P43
+ [7]
Action
inhibitors
Mechanism
IL-12 inhibitors(Interleukin-12 inhibitors), IL-23 inhibitors(Interleukin-23 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ulcerative colitis, active moderate
Australia
11 Sep 2024
Ulcerative colitis, active severe
Australia
11 Sep 2024
Crohn's disease, active moderate
Canada
01 Aug 2024
Crohn's disease, active severe
Canada
01 Aug 2024
Arthritis, Psoriatic
South Korea
12 Jun 2024
Colitis, Ulcerative
South Korea
12 Jun 2024
Crohn Disease
South Korea
12 Jun 2024
Plaque psoriasis
South Korea
12 Jun 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PsoriasisPhase 1
United States
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
20
RT-111 0.50 mg
ewtqqzwnog(tgxvdatgis) = ksasxpcxyk zhldjsweup (majaakyrlj, 7)
Positive
05 Feb 2024
RT-111 0.75 mg
ewtqqzwnog(tgxvdatgis) = tdnxstyxwg zhldjsweup (majaakyrlj, 8)
Phase 3
509
lycpfjfulp(upjpsorbqq) = accbundgmp fjdqcynpny (wnvlkfijnv )
Similar
01 Jan 2024
lycpfjfulp(upjpsorbqq) = mrqftfjxmt fjdqcynpny (wnvlkfijnv )
Phase 3
509
zkbqzisvwl(ijwpczdmio) = frpxbwbrix tmpmikbkzn (zdnhfqjqde, 1.771)
-
05 Jun 2023
Phase 3
509
donkxjqdur(uoaybonodp) = no hypersensitivity or malignancy were reported up to Week 28 ioedsfxpea (fnmbjzulzr )
Positive
07 Sep 2022
UST 45 mg
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free